Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - model
19
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Murine
Model
of Niemann-Pick Disease Type C
This technology includes a transgenic mouse
model
of Niemann-Pick Disease Type C (NPC), which is a rare neurodegenerative disorder, characterized by intracellular accumulation of cholesterol and gangliosides. The mouse strain, Tg(Npcl), expresses wild-type NPC1 gene under the control of the prion promoter. When combined with the NPC deficient mouse...
Published: 10/28/2024
|
Inventor(s):
Stacie Loftus
,
William ("Bill") Pavan
Keywords(s):
C
,
Disease
,
Listed LPM Maddox as of 4/15/2015
,
Model
,
Murine
,
NIEMANN-PICK
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
RXXXXX
,
VEXXXX
,
VHXXXX
,
VNXXXX
,
VPXXXX
,
WIXXXX
,
WKXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Psychiatry/Mental Health
,
Application > Therapeutics
,
TherapeuticArea > Endocrinology
,
TherapeuticArea > Dental
,
TherapeuticArea > Oncology
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Neurology
,
Application > Research Materials
,
TherapeuticArea > Ophthalmology
Mouse
Model
of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development
Children with Hutchinson-Gilford progeria syndrome (HGPS) suffer from acceleration of certain aging symptoms, mainly cardiovascular disease that generally leads to death from myocardial infarction and/or stroke. The cause of HGPS has been discovered to be a de novo point mutation in lamin A (LNMA) gene. NHGRI Scientist have generated a transgenic...
Published: 10/28/2024
|
Inventor(s):
Francis Collins
,
Maria Eriksson
,
Renee Varga
,
Michael Erdos
Keywords(s):
Abnormalities
,
HGPS
,
Hutchinson-Gilford
,
Listed LPM Maddox as of 4/15/2015
,
Model
,
Mouse
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Progeria
,
RXXXXX
,
Syndrome
,
vascular
,
VEXXXX
,
VPXXXX
,
XEXXXX
Category(s):
Application > Research Materials
,
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
,
TherapeuticArea > Endocrinology
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Dental
,
TherapeuticArea > Oncology
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Neurology
Mouse
Model
Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies
This technology includes a high-yield, easy-to-culture mouse neuronal cell
model
with nearly complete glucocerebrosidase deficiency representative of Gaucher disease (GD) to study pathophysiology and evaluate new therapies. GD is an autosomal recessive lysosomal storage disorder caused by loss-of function mutations in the GBA1 gene, which codes for...
Published: 10/28/2024
|
Inventor(s):
Matthew Nguyen
,
Wendy Westbroek
,
Nahid Tayebi
,
Ellen Sidransky
Keywords(s):
Cell
,
DEFICIENT
,
Disease
,
Gaucher
,
GLUCOCEREBROSIDASE
,
Line
,
Model
,
Mouse
,
NEURONAL
,
VEXXXX
,
VPXXXX
,
WIXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Neurology
,
Application > Research Materials
,
TherapeuticArea > Dental
,
Application > Therapeutics
,
TherapeuticArea > Oncology
,
TherapeuticArea > Endocrinology
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Infectious Disease
Novel mouse
model
of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency
Methylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. A well-characterized human mutation, p.G717V, has been introduced into mice. This mutation...
Published: 10/28/2024
|
Inventor(s):
Randy Chandler
,
Eirini (Irini) Manoli
,
Charles Venditti
Keywords(s):
:
,
Acidemia
,
CBAMutG715V
,
Methylmalonic
,
MMA
,
Model
,
Mouse
,
MUT
,
Mut-
,
Mut-/-
,
Novel
,
Partial-deficiency
,
Tg
,
VPXXXX
,
WIXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Ophthalmology
,
Application > Research Materials
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
TherapeuticArea > Endocrinology
,
TherapeuticArea > Dental
,
TherapeuticArea > Infectious Disease
Novel mouse
model
of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut
Methylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. Deletion of Mut in mice results in neonathal lethality, thus, to overcome this limitation,...
Published: 10/28/2024
|
Inventor(s):
Eirini (Irini) Manoli
,
Randy Chandler
,
Charles Venditti
Keywords(s):
Acidemia
,
INS-Mck-Mut
,
Methylmalonic
,
MMA
,
Model
,
Mouse
,
Mut-/-
,
Novel
,
Tg
,
VPXXXX
,
WIXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Cardiology
,
TherapeuticArea > Oncology
,
TherapeuticArea > Dental
,
TherapeuticArea > Endocrinology
,
Application > Therapeutics
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
Mouse
Model
of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies
Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. Most affected individuals display severe multisystemic disease characterized by metabolic instability, chronic renal disease, and neurological complications. Patients with the cobalamin A (cblA) subtype of MMA can have variable...
Published: 10/28/2024
|
Inventor(s):
Eirini (Irini) Manoli
,
Charles Venditti
Keywords(s):
Acidemia
,
cblA
,
Class
,
Cobalamin
,
ISOLATED
,
Methylmalonic
,
MMA
,
Model
,
Mouse
,
VEXXXX
,
VPXXXX
,
WKXXXX
,
XCXXXX
Category(s):
TherapeuticArea > Oncology
,
TherapeuticArea > Neurology
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Endocrinology
,
Application > Therapeutics
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Dental
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
Application > Diagnostics
Chlamydial Vaccine Technologies
The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia...
Published: 10/28/2024
|
Inventor(s):
Laszlo Kari
,
Deborah Crane
,
Harlan Caldwell
Keywords(s):
Against
,
Attenuated
,
-Attenuated
,
Bacterial strains
,
Blinding
,
Chlamydia
,
DA3XXX
,
DC4XXX
,
DCXXXX
,
DD1XXX
,
DDXXXX
,
DISEASES
,
Human
,
Immunogenic
,
Listed LPM Stansberry as of 4/15/2015
,
Live
,
Model
,
MULTIPLE
,
NON
,
Patent Category - Biotechnology
,
Plasmid-deficient
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
primate
,
Protective
,
RM
,
SAFE
,
Sexually
,
Strain
,
Trachoma
,
TRACHOMATIS
,
Transmitted
,
UBXXXX
,
Vaccine
,
VJXXXX
,
WIXXXX
,
WNXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
TherapeuticArea > Rare / Neglected Diseases
,
Application > Diagnostics
Diagnostic Antigens for the Identification of Latent Tuberculosis Infection
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine...
Published: 10/28/2024
|
Inventor(s):
Manon Deslauriers
,
Kristin Birkness
,
Peter King
,
Bernard Beall
,
Frederick Quinn
Keywords(s):
ANTIGENS
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DA3XXX
,
DAXXXX
,
DC4XXX
,
DCXXXX
,
DDXXXX
,
DEXXXX
,
diagnostic
,
DXXXXX
,
Granuloma
,
Human
,
IA3XXX
,
Identification
,
Latent
,
Methods
,
Model
,
OID-NCHHSTP-DTE
,
TUBERCULOSIS
,
VAXXXX
,
Vitro
,
VJXXXX
,
WBXXXX
,
WFXXXX
,
WIXXXX
,
XAXXXX
,
XCXXXX
,
YBXXXX
,
YDXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Geriatrics
,
TherapeuticArea > Immunology
,
Application > Consumer Products
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
Application > Diagnostics
,
ResearchProducts > Antibodies
,
Application > Vaccines
,
Application > Occupational Safety and Health
Novel In Vitro Granuloma
Model
for Studying Tuberculosis and Drug Efficacy
CDC researchers have developed an in vitro
model
system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and...
Published: 10/28/2024
|
Inventor(s):
Manon Deslauriers
,
Kristin Birkness
,
Peter King
,
Bernard Beall
,
Frederick Quinn
Keywords(s):
AC4XXX
,
AC5XXX
,
ACXXXX
,
ANTIGENS
,
AXXXXX
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DA3XXX
,
DAXXXX
,
DC4XXX
,
DCXXXX
,
DDXXXX
,
DEXXXX
,
diagnostic
,
DXXXXX
,
Granuloma
,
Human
,
IA3XXX
,
Identification
,
Latent
,
Methods
,
Model
,
OID-NCHHSTP-DTE
,
TUBERCULOSIS
,
Vitro
,
VJXXXX
,
WBXXXX
,
WFXXXX
,
WIXXXX
,
WMXXXX
,
XHXXXX
,
YBXXXX
,
YFXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Infectious Disease
,
Application > Vaccines
,
Application > Consumer Products
,
Application > Occupational Safety and Health
,
ResearchProducts > Research Equipment
,
TherapeuticArea > Immunology
,
Application > Research Materials
,
Application > Diagnostics
Mouse
Model
for Methylmalonic Acidemia, an Inherited Metabolic Disorder
Methylmalonic Acidemia (MMA) is a metabolic disorder affecting 1 in 25,000 to 48,000 individuals globally. MMA is characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. About 60% of MMA cases stem from mutations in the methylmalonyl...
Published: 10/28/2024
|
Inventor(s):
Eirini (Irini) Manoli
,
Charles Venditti
Keywords(s):
Dysfunction
,
metabolic disorder
,
Methylmalonic acidemia
,
Methylmalonyl-CoA
,
methylmalonyl-CoA mutase
,
MITOCHONDRIAL
,
MMA
,
Model
,
Mouse
,
MUT
,
RENAL
,
RXXXXX
,
TRANSGENIC
,
transgenic mouse
,
YAXXXX
,
YBXXXX
,
YCXXXX
Category(s):
Collaboration Sought > Collaboration
,
Application > Research Materials
1
2